A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.

Also called NCT01698775

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 213 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01698775
  • EudraCT 2012-002332-85
Other papers using this trial's data
  • A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment International journal of clinical practice, 2017-06 DOI, PubMed 28449320, PMC6681174 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01698775. Randomized; triple masking; primary purpose treatment. Start 2012-10-02 (actual); primary completion 2016-01-19 (actual). Results posted on 2017-02-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Placebo to omarigliptin
Intervention (Drug)
Glipizide
Intervention (Drug)
Placebo to glipizide
Intervention (Biological)
Insulin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01698775
Content hash
d50cbeae00c3789ec328cc5690e130f84450c48ab64bfdcc326949494ef69a04